We are Antioxidant GS CAS:123968-25-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests
SPECIFICATIONS AND PHYSICAL CHARACTERISTICS
TEST | UNIT | SPECIFICATION |
APPEARANCE | WHITE POWDER | |
MELTING POINT | ℃ | 117.0-120.0 |
PURITY(GC) | % | 98.0MIN |
LOSS ON DRYING | % | 0.50MAX |
PRODUCT FEATURES AND APPLICATIONS
● GS is a multifunctional antioxidant for the stabilization of adhesives, elastomers, and plastics. Unlike conventional phenolic antioxidants, GS is effective to scavenge alkyl (carbon-centered) radicals. The product is particularly active under demanding processing conditions (high temperature, high shear) and under anaerobic conditions.
● GS is particularly useful for the stabilization of plastics and elastomers derived from butadiene and other dienes, for example polybutadiene and copolymers of polybutadiene and other monomers. The product is also effective in the stabilization of polyolefins and polyamides.
● GS has highly effective to prevent gel formation in butadiene homo- and co-polymers, especially during processing under anaerobic conditions.
● GS non-discoloring and low volatility.
● GS has FDA-cleared for use in polypropylene, styrenic block copolymers, polystyrene, and rubber-modified polystyrene.
PACKAGE
20 KG CARTON
HANDLING AND STORAGE
Keep container tightly closed and dry and storage in cool place
Related News: The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.1-benzoyl-3-(3-methylphenyl)-2-thiourea The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.Carbonato de 1-cloroetil ciclohexilo CAS:99464-83-2 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.67443-38-3 Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.’s governing body.We partner with life science companies of all sizes, drawing on over 20 years of industry experience.
Product Name | |
---|---|
6-Hydroxy-7-methoxy-3,4-dihydroquinazolin-4-one Cas:179688-52-9 | View Details |
2,5-Dimethyl-1,4-dithiane-2,5-diol | View Details |
DL-Tartaric Acid Cas:133-37-9 | View Details |